The Netherlands: The effects of lack of harmonisation

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

The Netherlands: The effects of lack of harmonisation

A number of court cases were recently and are still playing between Becton Dickinson (BD) and Braun on the validity and infringement of EP 2319556 related to a needle tip for hypodermic needles.

These cases show that a harmonised court system (such as the Unified Patent Court) is needed to come to uniform decisions all over Europe.

The patent was granted in 2013 and attracted an opposition by BD, which was rejected by the opposition division of the European Patent Office. The appeal against this decision from BD was also rejected and the patent was maintained as granted.

Already during the opposition and appeal, Braun started several court actions. In a first instance case in Germany, the Düsseldorf court decided that the patent was infringed by BD. An appeal against this decision is pending. In relation to these German proceedings, a revocation suit was filed with the court in Munich and in a preliminary opinion this court decided that the patent lacks novelty and inventive step. The same case was filed in Austria and there the first instance court did not provide an injunction. However, on appeal the Austrian Supreme Court decided that the patent was valid and infringed. Also in Belgium a case has started but no decision or preliminary opinion is available yet.

In the present (first instance) case in The Netherlands (Court The Hague, September 6 2017, ECLI:NL:RBDHA: 2017:9997) the court has decided that the patent is invalid. However, in contrast to the decision in Germany, the basis of the invalidity was formed by extension of subject matter and lack of inventive step.

The decision on basis of extended subject matter is remarkable, since the interpretation of the technical content of the claims deviates from the interpretation of the Board of Appeal of the EPO. According to the Dutch court the intended interpretation as now used for the claims was not directly and unambiguously derivable from the application as filed.

Although a number of court cases (including the present Dutch one) have not been finally decided and appeals are pending, the case again illustrates that national courts and the EPO Board can come to deviating decisions on the same European patent. The case thus again illustrates the need for a Unified Patent Court.

Bart van Wezenbeek



V.O.

Johan de Wittlaan 7

2517 JR The Hague

The Netherlands

Tel: +31 70 416 67 11

Fax: +31 70 416 67 99

info@vo.eu

www.vo.eu

more from across site and SHARED ros bottom lb

More from across our site

The firm said adding capability in the French capital completes its coverage of all major patent litigation jurisdictions as it strives for UPC excellence
Marc Fenster explains how keeping the jury focused on the most relevant facts helped secure a $279m win for his client against Samsung
Clients are divided on what externally funded IP firms bring to the table, so those firms must prove why the benefits outweigh the downsides
Rahul Bhartiya, AI coordinator at the EUIPO, discusses the office’s strategy, collaboration with other IP offices, and getting rid of routine tasks
A boom in transactional work and a heightened awareness of IP have helped boost revenue for the rebranded commercial services team
Clemens Heusch, head of global litigation and dispute resolution at Nokia, tells us why open conversations – and respectful challenges – lead to the best results
Siegmund Gutman, who joined Mintz one year ago, explains the firm’s approach to life sciences litigation and what it means for hiring plans
The merger of two IP boutiques could prompt others to follow suit and challenge Australia’s externally funded firms
Law firm leaders say they are eager to make the most out of the market following a 'surprising' survey on in-house interest in IP monetisation
A defeat for AstraZeneca and Open Innovation Network's 20th anniversary were also among the top talking points this week
Gift this article